November 2016
 
Table of Contents
 


Funding Opportunities


Examination of Survivorship Care Planning Efficacy and Impact (R01)

 

National Cancer Institute Program Project Applications (P01)

 

 

 

View a full list of current funding opportunities. 




Open
Recruitments
Highlighted positions related to cancer for which VCU is currently hiring. View the full list.

 

Chair, Division of Epidemiology (F52780)

 

 

Shared Resource Spotlight
Vectra 3.0 Automated Quantitative Pathology Imaging System

Coming soon to the Cancer Mouse Models Core (CMMC), the fully automated Vectra® 3, 200-slide quantitative pathology imaging system is a state-of-the-art instrument for extracting proteomic and morphometric information from intact FFPE tissue sections or TMAs. Vectra 3 and inForm software analysis combine the power of multiplexed biomarker imaging and quantitative analysis all within a familiar digital workflow to accelerate cancer research. This instrument should be available by March 2017. The CMMC offers services and expertise that facilitate preclinical mouse models to support the development of novel cancer therapeutics and precision medicine.

Please visit this site for more information or contact CMMC Director Jennifer Koblinski, Ph.D., jennifer.koblinski@vcuhealth.org, or visit the  CMMC website .

Leaders' Update Update 
 
A message from Director Gordon Ginder

Massey's NCI Site Visit for the renewal of our Cancer Center Support Grant was held on September 29. The cancer center's leaders presented to a group of peer reviewers and NCI staff on Massey's accomplishments in the past five years since we were last reviewed and our plans for the next five years. 

 

This message continues with more about:

--Massey's progress over the last half decade, such as growth in peer-reviewed research funding, scientific publications, translational trials and cancer center membership

--The involvement of trainees in Massey research

--The impact of Massey's science on the catchment area

--Massey's Vision 2021 strategic plan priorities

--The addition of two new leadership positions to support strategic goals

 

Research HighlightsHighlights
Phase 2 clinical trial demonstrates repeat breast conservation is safe and effective
 
Douglas Arthur, M.D.
Developmental Therapeutics member
Massey physician-researcher Douglas Arthur was the lead author of a phase 2 clinical trial that demonstrated partial breast irradiation with 3D conformal radiation therapy, following second lumpectomy for patients experiencing in-breast failures after whole breast irradiation, is successful and achieved high local control at three years. The goal of the prospective, three-year study was to determine the associated toxicity, tolerance and safety of partial breast irradiation.

 

International study finds promise in new class of anti-cancer drugs
 
Nicholas Farrell, Ph.D.
Developmental Therapeutics  member
Massey researchers discovered that a new class of platinum-based drugs possesses significant anti-metastatic effects in fighting cancer. A recent study led by Nicholas Farrell, published in Chemical Science, found that polynuclear platinum-based drugs are effective by identifying new targets in tumor cells, which had previously been unidentified for this type of anti-cancer drug. The study results could lead to the expansion of cancers treatable by platinum-based drugs and possibly to the production of more cancer-specific drugs.

 

Center News Center1
Massey debuts new brand video during Olympics opening ceremony

Massey debuted a new brand video during the 2016 Summer Olympics opening ceremony. Several shorter TV spots were aired throughout the broadcast of the Olympic games, prior to local coverage of the Stand Up To Cancer telethon and around the NCI site visit at Massey. The video has also been shared online and through digital ads and more TV flights are planned. The video highlights Massey's mission to work toward a future without cancer.
Researcher Recognition Recognition
Huang awarded $1.5M to study enzyme's role and relationship to the growth of melanoma and colorectal cancer

Developmental Therapeutics
member
Massey physician-researcher Rong Huang, Ph.D., was awarded a $1.5 million grant from the National Institute of General Medical Sciences for a five-year study on the structure, transformation and impacts of protein alpha-N-terminal methylation. This methylation plays an essential role in regulating cell mitosis, chromatin interactions and DNA repair, and it was previously implicated to be involved in the development of malignant melanoma and colorectal cancer cells. Huang plans to elucidate the biochemical pathways through which these enzymes contribute to cancer growth, and, which in turn, could potentially lead to new, effective cancer therapies.



For a full listing of events, 

mediaMassey in the Media
 

NewsTop Cancer News
  
U.S. Centers for Disease Control and Prevention
Share with us your research, awards and accomplishments!
Submit your news to Blake Belden at beldenba@vcu.edu or (804) 628-4578.
  Connect with us!
Join Massey's online communities.
Like us on Facebook
Follow us on Twitter
View our videos on YouTube